HealthEquity (HQY)
(Delayed Data from NSDQ)
$78.63 USD
-0.93 (-1.17%)
Updated Sep 3, 2024 04:00 PM ET
After-Market: $78.84 +0.21 (0.27%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$78.63 USD
-0.93 (-1.17%)
Updated Sep 3, 2024 04:00 PM ET
After-Market: $78.84 +0.21 (0.27%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth F Momentum C VGM
Zacks News
Here's Why You Should Retain HealthEquity Stock for Now
by Zacks Equity Research
Investor confidence remains high in HealthEquity (HQY) stock, thanks to solid prospects.
HealthEquity (HQY) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
HealthEquity's (HQY) fiscal fourth-quarter earnings benefit from higher revenues and solid performing Service, Custodial and Interchange segments.
HealthEquity (HQY) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
HealthEquity (HQY) delivered earnings and revenue surprises of 14.71% and 1.36%, respectively, for the quarter ended January 2020. Do the numbers hold clues to what lies ahead for the stock?
Why HealthEquity (HQY) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
HealthEquity (HQY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why HealthEquity (HQY) Might Surprise This Earnings Season
by Zacks Equity Research
HealthEquity (HQY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
HealthEquity (HQY) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
HealthEquity (HQY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Teladoc (TDOC) Up 49% Year to Date: Will the Rally Continue?
by Zacks Equity Research
Teladoc (TDOC) benefits from its fast growing healthcare business and international expansion.
5 Top Stocks With Great Earnings Beat Potential
by Sanghamitra Saha
These top-ranked stocks are likely to beat on the bottom line in their next release.
Veeva Systems (VEEV) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Veeva Systems (VEEV) fiscal fourth-quarter results are likely to reflect robust product portfolio and higher revenues.
DENTSPLY SIRONA (XRAY) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) fourth-quarter performance to reflect better-than-expected performance at Technology & Equipment and growth in emerging markets.
What's in Store for Fulgent Genetics (FLGT) Q4 Earnings?
by Zacks Equity Research
Fulgent Genetics' (FLGT) fourth-quarter 2019 earnings are likely to reflect top-line growth and elevated test volumes.
What's in Store for GW Pharmaceuticals' (GWPH) Q4 Earnings?
by Zacks Equity Research
GW Pharmaceuticals (GWPH) Q4 results likely to reflect top-line growth on strong adoption of Epidiolex and Sativex.
HealthEquity (HQY) Stock Up on Solid Fiscal 2020 Results
by Zacks Equity Research
HealthEquity (HQY) raises fiscal 2020 view for top and bottom line.
3 Medical Product Stocks Likely to Beat This Earnings Season
by Trina Mukherjee
Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.
Sonoco (SON) Meets Q4 Earnings Estimates
by Zacks Equity Research
Sonoco (SON) delivered earnings and revenue surprises of 0.00% and 0.35%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
HealthEquity (HQY) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
HealthEquity's (HQY) fourth-quarter fiscal 2020 earnings are likely to reflect top-line growth and higher HSA member growth.
Global Industrial Unit to Drive Ecolab's (ECL) Q4 Earnings
by Zacks Equity Research
Ecolab's (ECL) Q4 results are likely to reflect strength in core Global Industrial unit.
AMN vs. HQY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
AMN vs. HQY: Which Stock Is the Better Value Option?
Here's Why You Should Hold on to OPKO Health Stock for Now
by Zacks Equity Research
OPKO Health (OPK) continues to gain from RAYALDEE and BioReference platforms, and focus on R&D despite operating losses.
ABIOMED (ABMD) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Flagship Impella likely to have boosted ABIOMED's (ABMD) fiscal Q3 earnings.
Bet on Earnings Beat With 5 Top-Ranked Stocks
by Sanghamitra Saha
These top-ranked stocks are likely to beat on bottom line in their next releases.
Varian (VAR) Earnings and Revenues Miss Estimates in Q1
by Zacks Equity Research
Varian (VAR) gains from core Oncology segment in fiscal Q1.
Quest Diagnostics (DGX) Hits a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Quest Diagnostics (DGX) gains from several positive developments like partnerships and acquisitions.
Accuray (ARAY) Q2 Earnings Top Estimates, Gross Orders Fall
by Zacks Equity Research
Service revenues drive Accuray's (ARAY) Q2 results, gross margin expands.
Here's Why You Should Add HealthEquity (HQY) to Portfolio Now
by Zacks Equity Research
Solid prospects in the HSA industry consistently drive HealthEquity (HQY).